Latanoprost sustained release implant - Pfizer/EyePoint Pharmaceuticals

Drug Profile

Latanoprost sustained release implant - Pfizer/EyePoint Pharmaceuticals

Alternative Names: Latanoprost slow release insert - Pfizer/EyePoint Pharmaceuticals; Latanoprost SR insert - Pfizer/EyePoint Pharmaceuticals; Sustained release latanoprost device - Pfizer/EyePoint Pharmaceuticals

Latest Information Update: 05 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer; pSivida
  • Developer EyePoint Pharmaceuticals; Pfizer; University of Kentucky
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Ocular hypertension; Open-angle glaucoma

Most Recent Events

  • 28 Mar 2018 pSivida is now called EyePoint Pharmaceuticals
  • 30 Jun 2015 Latanoprost sustained release implant is still in phase I/II trials for Ocular hypertension and Open angle glaucoma in USA
  • 07 Dec 2014 Pfizer terminates phase I/II trial in Open angle glaucoma and Ocular hypertension in USA (NCT01180062)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top